Ignite Creation Date:
2025-12-24 @ 10:57 PM
Ignite Modification Date:
2026-02-23 @ 8:09 PM
Study NCT ID:
NCT02955069
Status:
COMPLETED
Last Update Posted:
2021-04-12
First Post:
2016-11-02
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-02-14
Start Date Type:
ACTUAL
Primary Completion Date:
2018-08-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-05-13
Completion Date Type:
ACTUAL
First Submit Date:
2016-11-02
First Submit QC Date:
None
Study First Post Date:
2016-11-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-03-16
Results First Submit QC Date:
None
Results First Post Date:
2021-04-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2019-04-22
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2021-03-16
Last Update Post Date:
2021-04-12
Last Update Post Date Type:
ACTUAL